rigi
like
receptor
pathway
stimul
rna
viru
infect
interact
cytosol
rigi
viral
rna
structur
contain
short
hairpin
dsrna
triphosph
termin
structur
present
studi
rna
agonist
rigi
synthes
vitro
shown
stimul
rigidepend
antivir
respons
concentr
picomolar
rang
human
lung
epitheli
cell
specif
stimul
multipl
paramet
innat
antivir
respons
includ
activ
induct
inflammatori
interferon
stimul
gene
hallmark
fulli
function
antivir
respons
evalu
magnitud
durat
gene
express
transcript
profil
identifi
robust
sustain
diversifi
antivir
inflammatori
respons
character
enhanc
pathogen
recognit
interferon
ifn
signal
bioinformat
analysi
identifi
transcript
signatur
uniqu
induc
includ
constel
nfkb
target
gene
capabl
mobil
multipl
arm
innat
adapt
immun
respons
treatment
primari
pbmc
lung
epitheli
cell
provid
signific
protect
spectrum
rna
dna
virus
mice
intraven
administr
protect
anim
lethal
challeng
influenza
reduc
viru
titer
mous
lung
protect
anim
virusinduc
pneumonia
strikingli
rigispecif
transcript
respons
afford
partial
protect
influenza
challeng
even
absenc
type
interferon
signal
system
approach
provid
transcript
biochem
vivo
analysi
antivir
efficaci
highlight
therapeut
potenti
associ
use
rigi
agonist
broad
spectrum
antivir
agent
innat
immun
system
evolv
numer
molecular
sensor
signal
pathway
detect
contain
clear
viral
infect
virus
sens
subset
pattern
recognit
receptor
prr
recogn
evolutionarili
conserv
structur
known
pathogenassoci
molecular
pattern
pamp
classic
viral
nucleic
acid
predomin
pamp
detect
receptor
infect
sens
step
contribut
activ
signal
cascad
culmin
earli
product
antivir
effector
molecul
cytokin
chemokin
respons
inhibit
viral
replic
induct
adapt
immun
respons
addit
nucleic
acid
sens
subset
endosomeassoci
tolllik
receptor
tlr
viral
rna
structur
within
cytoplasm
recogn
member
retino
acidinduc
genei
rigi
like
receptor
rlr
famili
includ
three
dexdh
box
rna
helicas
rigi
rigi
cytosol
multidomain
protein
detect
viral
rna
helicas
domain
addit
rna
sens
domain
rigi
also
possess
effector
caspas
activ
recruit
domain
card
interact
mitochondri
adaptor
mav
also
known
visa
cardif
viral
rna
bind
alter
rigi
conform
autoinhibitori
state
open
conform
expos
card
domain
result
gener
activ
state
character
atp
hydrolysi
atpdriven
transloc
rna
activ
rigi
also
allow
ubiquitin
andor
bind
polyubiquitin
recent
studi
polyubiquitin
bind
shown
induc
format
rigi
tetram
activ
downstream
signal
induc
format
prionlik
fibril
compos
mav
adaptor
mav
trigger
activ
nfkb
transcript
protein
ikkrel
serin
kinas
ikk
lead
primari
activ
antivir
program
involv
product
type
interferon
ifnb
ifna
well
proinflammatori
cytokin
antivir
factor
secondari
respons
involv
induct
ifn
stimul
gene
isg
induc
bind
ifn
cognat
receptor
ifna
br
trigger
jakstat
pathway
amplifi
antivir
immun
respons
natur
ligand
recogn
rigi
subject
intens
studi
given
pamp
initi
trigger
antivir
immun
respons
vitro
synthes
rna
carri
expos
termin
triphosph
moieti
first
identifi
rigi
agonist
moieti
present
end
viral
self
rna
molecul
gener
rna
polymer
howev
eukaryot
cell
rna
process
nucleu
cleav
end
rna
cap
prior
releas
cytoplasm
mechan
distinguish
viral
nonself
cellular
self
rna
render
recogniz
innat
rigi
sensor
character
rna
structur
demonstr
blunt
base
pair
end
rna
minimum
doubl
strand
ds
length
nucleotid
also
import
rigi
signal
furthermor
short
dsrna
bp
trigger
rigi
wherea
long
dsrna
bp
poli
c
lack
fail
trigger
rigi
recogn
natur
rna
extract
viral
infect
cell
specif
viral
rna
genom
viral
replic
intermedi
also
shown
activ
rigi
interestingli
highli
conserv
untransl
region
utr
neg
singl
strand
rna
viru
genom
display
high
base
pair
complementar
panhandl
structur
theoret
form
viral
genom
meet
requir
rigi
recognit
elucid
crystal
structur
rigi
highlight
molecular
interact
rigi
dsrna
provid
structur
basi
conform
chang
involv
expos
card
domain
effect
downstream
signal
given
level
molecular
understand
rigi
ligand
subsequ
signal
lead
induct
antivir
immun
respons
sought
investig
rang
protect
innat
immun
respons
trigger
rigi
agonist
viral
infect
short
vitrosynthes
deriv
utr
vsv
genom
activ
rigi
signal
pathway
trigger
robust
antivir
respons
interf
infect
sever
pathogen
virus
includ
dengu
hcv
influenza
furthermor
intraven
deliveri
rna
agonist
stimul
antivir
state
vivo
protect
mice
lethal
influenza
viru
challeng
report
highlight
therapeut
potenti
natur
deriv
rigi
agonist
potent
stimul
innat
antivir
respons
capac
mobil
gene
essenti
gener
effici
immun
multipl
infect
stimul
antivir
respons
lung
epitheli
cell
triphosph
contain
rna
deriv
utr
negativestrand
rna
viru
vesicular
stomat
viru
vsv
gener
vitro
transcript
use
polymeras
enzymat
reaction
synthes
rna
molecul
terminu
predict
panhandl
secondari
structur
depict
fig
gel
analysi
nucleas
sensit
confirm
gener
singl
rna
product
expect
size
nucleotid
transfect
increas
amount
result
phosphoryl
h
hallmark
immedi
earli
activ
antivir
respons
fig
lane
induct
apoptosi
detect
follow
treatment
higher
concentr
proapoptot
protein
noxa
direct
transcript
target
well
cleavag
product
caspas
parp
upregul
dose
depend
manner
fig
lane
optim
induct
antivir
signal
limit
cytotox
achiev
concentr
ngml
pm
fig
lane
importantli
stimul
immun
signal
apoptosi
depend
moieti
homolog
rna
without
terminu
abrog
stimul
rang
rna
concentr
fig
lane
character
antivir
respons
trigger
kinet
downstream
rigi
signal
measur
differ
time
h
stimul
cell
fig
homodimer
st
panel
phosphoryl
nd
panel
detect
earli
h
post
treatment
sustain
h
use
newli
character
antibodi
induct
endogen
detect
kinet
delay
compar
activ
th
vs
rd
panel
ikba
phosphoryl
likewis
detect
earli
h
posttreat
sustain
cell
th
panel
altogeth
nfkb
requir
optim
induct
ifnb
promot
jakstat
signal
detect
h
phosphoryl
th
panel
well
later
accumul
h
th
panel
rigi
upregul
h
posttreat
th
th
panel
wherea
second
group
isg
develop
safe
effect
drug
inhibit
viru
replic
remain
challeng
activ
natur
host
defens
use
interferon
ifn
therapi
proven
effect
treatment
certain
viral
infect
distinct
variat
concept
analyz
capac
small
rna
molecul
mimic
viral
compon
trigger
host
antivir
respons
inhibit
replic
sever
pathogen
human
virus
use
gene
express
profil
identifi
robust
antivir
inflammatori
gene
signatur
treatment
contain
rna
includ
integr
set
gene
regul
ifn
treatment
deliveri
lung
epitheli
cell
vitro
stimul
strong
antivir
immun
respons
inhibit
multipl
sever
virus
murin
model
influenza
infect
inocul
agonist
protect
anim
lethal
challeng
influenza
inhibit
viru
replic
mous
lung
first
h
infect
report
highlight
therapeut
potenti
natur
deriv
rigi
agonist
potent
stimul
innat
antivir
respons
capac
block
replic
divers
human
pathogen
virus
th
th
panel
induc
h
h
agonist
treatment
ifnb
detect
cell
cultur
supernat
earli
h
treatment
substanti
releas
pgml
peak
h
fig
top
panel
ifna
releas
detect
later
h
remain
high
thereaft
pgml
figur
thu
trigger
full
antivir
respons
demonstr
activ
transcript
factor
nfkb
releas
interferon
jakstat
pathway
activ
induct
isg
induct
antivir
respons
requir
intact
rigi
pathway
address
whether
exclus
activ
rigi
sensor
wild
type
mous
embryon
fibroblast
wt
mef
mef
cotransfect
type
ifn
report
construct
measur
promot
activ
activ
ifnb
promot
ifna
promot
wt
mef
promot
activ
depend
rigi
sinc
promot
stimul
mef
figur
stimul
antivir
inflammatori
respons
lung
epitheli
cell
schemat
represent
vsvderiv
gel
analysi
rna
oligonucleotid
deriv
untransl
region
utr
vsv
product
vitro
transcript
run
singl
product
degrad
rnase
b
homolog
control
rna
lack
end
mix
lipofectamin
rnaimax
transfect
differ
rna
concentr
ngml
cell
h
post
treatment
whole
cell
extract
wce
prepar
resolv
sdspage
analyz
immunoblot
noxa
cleav
caspas
parp
bactin
result
repres
experi
immunoblot
sampl
c
cell
transfect
ngml
wce
prepar
differ
time
transfect
h
subject
sdspage
probe
antibodi
rigi
ikba
ikba
bactin
immunoblot
sampl
detect
dimer
wce
resolv
nativepag
analyz
immunoblot
elisa
perform
cell
cultur
supernat
quantifi
releas
ifnb
ifna
time
error
bar
repres
sem
two
independ
sampl
posit
control
constitut
activ
card
domaincontain
rigi
mutant
use
bypass
requir
rigi
figur
furthermor
induct
ifn
respons
exclus
depend
intact
rigi
signal
sinc
ifnb
promot
activ
decreas
mef
figur
cell
treat
knock
rigi
abolish
phosphoryl
well
rigi
upregul
compar
control
sirnatr
cell
evalu
breadth
host
intrins
respons
result
rna
agonist
stimul
rigi
modul
transcriptom
cell
stimul
h
analys
gene
array
use
illumina
platform
figur
show
waterfal
plot
differenti
express
gene
deg
select
base
fold
chang
pvalu
stimul
number
gene
upregul
administr
steadili
increas
time
major
downregul
occur
h
fig
heatmap
present
deg
emphasi
highli
deregul
gene
time
fig
canon
pathway
analysi
use
ingenu
pathway
analysi
softwar
identifi
ifn
signal
activ
irf
cytosol
prr
signal
antigen
present
main
upregul
function
categori
function
relat
cell
metabol
cell
cycl
downregul
rigi
agonist
treatment
fig
subsequ
kinet
analysi
reveal
rigi
agonist
induc
distinct
tempor
pattern
gene
express
fig
exampl
gene
highli
express
earli
h
includ
ifnl
famili
express
gene
sustain
throughout
time
cours
decreas
h
fig
lest
panel
second
subset
gene
associ
antivir
respons
induc
earli
h
express
sustain
markedli
augment
h
exemplifi
ifi
famili
member
isg
fig
middl
panel
third
subset
gene
induc
primarili
later
time
point
part
secondari
respons
treatment
includ
hla
famili
fig
right
panel
repres
gene
differ
subset
valid
quantit
realtim
rtpcr
fig
overal
induc
robust
biphas
transcript
respons
character
strong
activ
antivir
inflammatori
gene
signatur
kinet
transcript
profil
mirror
biochem
activ
event
detect
figur
order
gain
systemswid
insight
rigi
transcriptom
function
cluster
deg
perform
function
cluster
identifi
varieti
transcript
subnetwork
biolog
process
regul
rigi
fig
expect
h
fig
induct
antivir
inflammatori
respons
program
downstream
irf
nfkb
stat
signal
identifi
fig
express
sever
cytokin
chemokin
gene
also
upregul
concomitantli
gene
relat
fo
tgfb
signal
well
hypox
signal
via
downregul
h
fig
gene
associ
pathogen
recognit
receptor
signal
ubiquitin
pathway
inflamm
apoptosi
also
induc
rigi
activ
interestingli
profil
downregul
gene
identifi
function
cluster
involv
cell
cycl
regul
myc
signal
heat
shock
respons
compar
analysi
gene
express
profil
respons
although
contribut
type
ifn
antivir
respons
stimul
unquestion
factor
may
also
augment
antivir
state
establish
defin
gene
uniqu
induc
gene
express
profil
cell
stimul
h
compar
heatmap
figur
display
express
profil
gene
differenti
upand
downregul
fold
chang
pvalu
ifn
black
blue
gene
exclus
red
green
gene
interestingli
induc
significantli
broader
gene
express
program
compar
especi
h
determin
whether
differ
gene
express
observ
due
suboptim
stimul
higher
concentr
within
rang
report
vitro
applic
test
treatment
ngml
equival
treatment
iuml
term
ifna
level
releas
cell
cultur
supernat
increas
concentr
iuml
correspond
level
ifna
greater
physiolog
secret
follow
ng
ml
treatment
pgml
vs
pgml
fig
regardless
amount
use
activ
cell
gene
express
level
remain
rel
unchang
fig
iuml
vs
iuml
indic
treatment
satur
remark
spectrum
gene
differenti
express
treatment
virtual
contain
within
transcriptom
induc
treatment
h
h
gene
fig
demonstr
induc
complet
ifn
respons
h
gene
characterist
activ
part
ifn
signatur
maxim
induc
fig
black
portion
comparison
also
highlight
fact
surprisingli
larg
number
gene
uniqu
regul
gene
h
gene
h
fig
notabl
three
member
ifnl
famili
well
cytokin
highli
induc
treatment
fig
red
gene
ifn
signal
highli
induc
treatment
strongli
activ
antigen
present
machineri
preferenti
stimul
dendrit
cell
matur
crosstalk
link
innat
adapt
immun
well
induct
wider
rang
signal
pathway
fig
significantli
preferenti
stimul
extens
induct
nfkb
signal
node
compar
treatment
fig
thu
treatment
besid
induc
complet
ifn
respons
addit
stimul
transcript
larg
uniqu
set
inflammatori
antivir
gene
determin
rigi
agonist
capabl
induc
function
antivir
respons
cell
treat
h
later
challeng
vsv
dengu
denv
vaccinia
virus
virus
establish
infect
untreat
cell
assess
flow
cytometri
respect
cell
vsv
denv
infect
reduc
infect
vaccinia
reduc
fig
releas
infecti
vsv
denv
viru
complet
block
treatment
pfuml
untreat
cell
respect
vs
undetect
treat
cell
fig
similarli
primari
human
monocyt
denv
infect
decreas
presenc
fraction
denv
infect
lower
likewis
inhibit
rna
agonist
treatment
fig
demonstr
requir
intracellular
deliveri
primari
cell
three
patient
treat
alon
transfect
reagent
alon
combin
denv
infect
reduc
upon
transfect
rna
agonist
fig
evalu
antivir
effect
hiv
infect
activ
cell
pretreat
supernat
isol
monocyt
infect
hivgfp
absenc
treatment
activ
cell
activ
infect
hiv
determin
gfp
express
flow
cytometri
wherea
infect
cell
treat
supernat
reduc
fig
also
antivir
effect
hcv
hepatocellular
carcinoma
cell
line
hcv
express
inhibit
treatment
fig
lane
vs
antivir
effect
fulli
depend
rigi
demonstr
cell
express
mutat
inact
rigi
absenc
upregul
follow
treatment
fig
lane
express
compar
untreat
hcvinfect
cell
fig
lane
vs
thu
broadspectrum
antivir
agent
abl
trigger
effici
innat
immun
respons
differ
cell
type
prevent
infect
rna
dna
virus
explor
inhibitori
potenti
cell
pretreat
h
infect
influenza
viru
increas
moi
influenza
replic
monitor
protein
express
fig
plaqu
assay
fig
viral
replic
block
pretreat
even
highest
moi
demonstr
complet
loss
express
decreas
viral
titer
moi
cell
pretreat
decreas
concentr
ngml
prior
influenza
viru
challeng
moi
significantli
block
influenza
replic
concentr
ngml
demonstr
reduct
protein
express
fig
lane
reduct
viru
titer
plaqu
assay
fig
demonstr
antivir
activ
influenza
reli
rigi
signal
cell
knock
rigi
infect
influenza
knockdown
isg
induc
fig
lane
vs
treatment
fail
inhibit
express
fig
lane
vs
indic
antivir
effect
exclus
depend
rigi
next
determin
whether
rigi
uniqu
gene
express
profil
character
figur
could
compens
ifn
respons
cell
knock
ifna
br
knock
effici
demonstr
absenc
rigi
induct
follow
stimul
fig
lane
interestingli
induct
isg
partial
reduc
follow
treatment
reduct
determin
potenti
vivo
mice
inocul
intraven
mg
complex
vivojetpei
transfect
reagent
stimul
potent
immun
respons
vivo
character
ifna
ifnb
secret
serum
lung
fig
well
antivir
gene
upregul
fig
respons
potent
rapid
serum
ifnb
level
increas
compar
basal
level
earli
h
post
administr
fig
top
left
panel
immun
activ
observ
vivo
correl
earli
transient
recruit
neutrophil
lung
along
sustain
increas
macrophag
dendrit
cell
popul
fig
next
determin
antivir
potenti
vivo
mice
treat
h
day
day
infect
day
lethal
inoculum
influenza
wherea
untreat
infect
mice
succumb
infect
day
mice
fulli
recov
surviv
fig
overal
weight
loss
similar
two
group
fig
although
notic
delay
day
onset
weight
loss
observ
anim
treat
mice
fulli
recov
within
day
fig
influenza
replic
lung
monitor
plaqu
assay
cours
infect
viru
titer
lung
untreat
mice
reach
maximum
day
postinfect
fig
decreas
viru
titer
note
day
postinfect
possibl
correl
onset
adapt
immun
anim
succumb
influenza
infect
day
fig
interestingli
treatment
inhibit
influenza
viru
replic
lung
earli
infect
within
first
h
fig
day
day
viru
titer
lung
increas
although
influenza
titer
still
lower
compar
titer
untreat
mice
fig
day
day
anim
control
infect
demonstr
decreas
viral
titer
continu
administr
h
interv
postinfect
addit
therapeut
effect
delay
viral
replic
fig
versu
dose
indic
antivir
immun
may
sustain
repetit
administr
furthermor
therapeut
administr
also
control
influenza
viral
replic
although
prophylact
treatment
effect
block
influenza
dissemin
lung
administr
rna
agonist
day
day
influenza
infect
also
reduc
viral
lung
titer
fig
antivir
respons
trigger
vivo
depend
intact
rigi
signal
serum
ifnb
releas
abolish
mice
wherea
absenc
affect
ifnb
releas
fig
agreement
mice
treat
control
influenza
lung
titer
increas
vs
wt
mice
titer
compar
untreat
wt
mice
fig
determin
whether
treatment
suffici
protect
influenza
absenc
ifn
signal
mice
treat
challeng
influenza
viru
untreat
anim
succumb
infect
anim
receiv
treatment
surviv
suggest
ifnindepend
effect
function
absenc
ifn
respons
thu
intraven
administr
stimul
potent
rapid
immun
respons
vivo
delay
influenza
viru
replic
lung
infect
anim
rescu
mice
lethal
inocul
influenza
evalu
effect
rna
agonist
administr
influenzamedi
patholog
histolog
section
lung
untreat
treat
mice
prepar
analys
treatment
alon
character
modest
rare
leukocytetoendothelium
attach
mix
leukocyt
popul
mononuclearpolymorphonuclear
infiltr
perivascular
space
h
inject
data
shown
infiltr
resolv
limit
endotheli
cell
attach
day
intraven
administr
fig
influenza
viru
infect
induc
sever
extens
inflamm
oedema
perivascular
space
bronchial
lumen
day
postinfect
anim
receiv
rna
agonist
influenza
trigger
mild
infrequ
inflamm
extend
bronchial
lumen
day
postinfect
epitheli
degener
loss
tissu
integr
sever
lung
untreat
infect
anim
correl
epitheli
hyperplasia
observ
later
time
compar
lung
anim
treat
inflamm
epitheli
damag
progress
untreat
mice
day
fig
correl
increas
viru
titer
lung
fig
inflamm
epitheli
damag
consist
less
appar
agonisttr
mice
strikingli
surfac
area
lung
affect
pneumonia
significantli
reduc
mice
compar
nontreat
mice
day
vs
day
vs
fig
bottom
panel
overal
influenzamedi
pneumonia
less
sever
anim
administ
influenza
challeng
demonstr
possess
antivir
effect
vivo
limit
influenza
replic
lung
limit
lung
damag
prevent
influenzamedi
pneumonia
mortal
rigi
agonist
attract
potenti
antivir
agent
trigger
innat
cytosol
rigi
pathway
mimic
earliest
step
immun
recognit
respons
viral
pathogen
present
studi
short
agonist
rigi
deriv
utr
vsv
genom
stimul
antivir
respons
protect
human
lung
epitheli
cell
human
pbmc
challeng
sever
virus
includ
denv
influenza
hiv
vsv
hcv
vaccinia
viru
intraven
administr
agonist
mice
stimul
antivir
state
vivo
protect
anim
lethal
influenza
viru
challeng
control
influenza
virusmedi
pneumonia
analysi
dynam
host
transcriptom
follow
stimul
character
antivir
inflamm
relat
gene
express
pattern
transcript
node
gene
regul
irf
nfkb
stat
famili
virtual
gene
activ
encompass
within
transcriptom
bioinformat
analysi
also
identifi
distinct
gene
pattern
function
process
uniqu
induc
inhibit
potenc
vitro
vivo
repres
specif
power
trigger
innat
immun
novel
approach
antivir
therapi
first
time
rnabas
agonist
rigi
shown
block
replic
multipl
virus
broadspectrum
antivir
activ
attribut
part
potent
stimul
inflammatori
antivir
respons
driven
earli
induct
irf
nfkb
stat
chemokin
proinflammatori
cytokin
gene
parallel
also
observ
inhibit
gene
involv
tgfb
signal
immunosuppress
natur
tgfb
pathway
inhibit
transcript
node
could
potenti
immun
activ
respons
agonist
emerg
apoptosi
ubiquitin
signal
node
later
time
h
suggest
role
cell
death
ubiquitinbas
signal
modif
antivir
respons
stimul
rigi
trigger
complet
ifn
respons
h
post
treatment
induc
express
gene
stimul
treatment
magnitud
isg
induct
enhanc
compar
profil
among
isg
tripartit
motif
contain
trim
protein
ifitm
protein
viperin
exemplifi
rang
isg
induc
rigi
implic
inhibitor
influenza
vsv
west
nile
dengu
hcv
recent
studi
high
throughput
screen
antivir
effector
identifi
panel
broadli
act
antivir
molecul
combin
express
multipl
isg
provid
addit
inhibitori
effect
hcv
replic
valid
antivir
isg
identifi
induc
includ
rigi
transcriptom
analysi
also
identifi
distinct
subset
gene
specif
induc
addit
synergist
enhanc
antivir
respons
stimul
treatment
bioinformat
analysi
identifi
uniqu
function
signatur
upregul
gene
involv
induc
wider
rang
signal
pathway
bridg
innat
adapt
immun
respons
import
gene
uniqu
induc
highlight
antivir
respons
limit
influenza
infect
vitro
vivo
even
absenc
function
type
ifn
signal
specul
extend
rang
gene
induc
compar
reflect
activ
multipl
signal
pathway
downstream
rigimav
versu
morelimit
transactiv
potenti
ifnregul
jakstat
axi
type
iii
ifn
among
highli
stimul
gene
uniqu
upregul
respons
recent
studi
demonstr
type
type
iii
ifn
activ
similar
compon
jakstat
pathway
although
type
iii
ifn
shown
prolong
activ
jakstat
signal
induc
delay
stronger
induct
isg
compar
type
ifn
ifnl
increasingli
implic
antivir
therapi
ifnl
administr
mice
stimul
express
protect
mice
lethal
influenza
challeng
block
replic
inhibit
viru
integr
posttranscript
event
combin
ifna
ifnc
enhanc
induct
antivir
gene
effect
inhibit
hcv
vsv
replic
addit
polymorph
near
gene
correl
spontan
treatmentinduc
clearanc
hepat
c
infect
ifnl
therapi
activ
investig
treatment
hcv
altogeth
result
indic
specif
induct
ifnl
may
contribut
immun
site
viral
infect
note
neg
regul
innat
immun
respons
also
detect
stimul
addit
induct
treatment
uniqu
neg
regul
activ
exclus
also
identifi
contribut
inhibit
jakstat
signal
henc
limit
amplif
ifn
respons
ikba
inhibit
activ
nfkb
signal
complex
would
prevent
excess
inflamm
observ
suggest
target
upstream
viral
sensor
may
provid
activ
well
neg
feedback
regul
termin
immun
respons
prevent
uncontrol
inflamm
approach
may
offer
advantag
ifn
therapi
term
limit
potenti
toxic
sideeffect
activ
rigi
signal
pathway
use
also
induc
integr
set
gene
pathway
effici
bridg
innat
adapt
immun
respons
util
multipl
arm
system
mobil
gene
enhanc
traffick
immun
cell
neutrophil
monocyt
memori
cell
b
cell
includ
mani
other
also
observ
induct
gene
import
activ
effector
arm
adapt
immun
system
shown
enhanc
cell
surviv
kill
potenti
cytokin
chemokin
certainli
play
role
initi
innat
adapt
immun
cell
respons
critic
gener
effici
immun
multipl
viral
infect
vivo
intraven
administr
rigi
agonist
stimul
potent
immun
respons
vivo
reach
lung
prevent
mortal
associ
viru
challeng
histopatholog
analysi
reveal
diminish
influenzamedi
lung
damag
recruit
inflammatori
cell
infect
lung
follow
treatment
rapid
control
viru
replic
demonstr
significantli
reduc
viru
titer
lung
within
day
viru
inocul
may
prevent
excess
immun
cell
recruit
earli
infect
influenza
infect
gener
complex
pathogenesi
mediat
part
viraland
immunemedi
damag
therefor
activ
recruit
limit
number
specif
immun
cell
type
neutrophil
alveolar
macrophag
dendrit
cell
may
gener
benefici
antivir
microenviron
addit
favor
initi
adapt
immun
respons
would
eventu
contribut
vivo
efficaci
agonist
group
recent
report
induc
protect
rigi
mediat
antivir
respons
inhibit
replic
influenza
viru
inhibit
influenza
infect
depend
moieti
secondari
ifn
respons
crucial
mount
effect
antivir
respons
recent
short
rna
molecul
dual
function
develop
sirna
influenza
np
gene
agonist
rigi
pathway
inhibit
influenza
infect
vitro
vivo
contribut
rigi
activ
inhibit
influenza
demonstr
defect
interf
rna
produc
sendai
viru
life
cycl
best
character
natur
rigi
ligand
known
induc
strong
inflammatori
respons
interestingli
molecul
adjuv
potenti
could
stimul
antibodydepend
respons
direct
influenza
antigen
compar
earlier
studi
adopt
system
approach
provid
biochem
transcript
biolog
mechanist
explan
antivir
efficaci
observ
vitro
vivo
activ
natur
host
defens
prevent
establish
dissemin
viral
infect
valuabl
altern
strategi
antivir
drug
specif
target
viral
process
interferon
therapi
use
clinic
two
decad
proven
effect
treatment
certain
viral
infect
mainli
hepat
b
hepat
c
well
malign
autoimmun
diseas
howev
ifn
therapi
also
associ
signific
side
effect
limit
use
polyi
c
anoth
dsrna
immun
modul
also
test
vitro
vivo
demonstr
efficaci
respiratori
infect
along
antivir
drug
vaccin
primari
approach
reduc
morbid
mortal
associ
viral
infect
increas
immunogen
vaccin
molecular
adjuv
elicit
cytokin
costimulatori
molecul
immunomodulatori
factor
enhanc
vaccineelicit
immun
respons
advantag
mimick
viral
recognit
trigger
immun
respons
analog
natur
viral
infect
furthermor
respons
stimul
reminisc
integr
multipot
respons
elicit
earli
follow
immun
protect
vaccin
identifi
far
yellow
fever
vaccin
therefor
immun
modul
rigi
agonist
may
function
antivir
therapeut
may
also
serv
vaccin
adjuv
increas
magnitud
antivir
immun
respons
elicit
vaccin
epitop
thu
present
studi
demonstr
prophylact
therapeut
antivir
potenti
also
open
door
investig
potenti
rigi
agonist
vaccin
adjuv
sequenc
deriv
utr
vsv
genom
previous
describ
vitro
transcrib
rna
prepar
use
ambion
megascript
high
yield
transcript
kit
accord
instruct
invitrogen
ny
usa
templat
consist
two
complementari
viral
sequenc
contain
promot
anneal
minut
cool
gradual
night
gac
gaa
gac
aaa
caa
acc
att
att
atc
att
aaa
att
tta
ttt
ttt
atc
tgg
ttt
tgt
ggt
ctt
cgt
cta
tag
tga
gtc
gta
tta
att
vitro
transcript
reaction
proceed
hour
purifi
isol
use
qiagen
mirna
mini
kit
md
usa
homolog
rna
without
moieti
purchas
idt
integr
dna
technolog
inc
iowa
usa
dephosphoryl
use
ciap
invitrogen
ny
usa
gener
ident
result
data
shown
secondari
structur
predict
use
rnafold
webserv
univers
vienna
vienna
austria
rna
analys
denatur
polyacrylamid
urea
gel
follow
digest
ngul
rnase
ambion
ca
usa
muul
dnase
ambion
ca
usa
min
cell
cultur
transfect
luciferas
assay
whole
cell
extract
prepar
lysi
buffer
mm
tri
ph
mm
nacl
mm
naf
mm
edta
glycerol
mm
na
vo
mm
bglycerophosph
mm
phenylmethylsulfonyl
fluorid
mgml
leupeptin
pepstatin
aproptinin
nonidet
wce
subject
electrophoresi
nativ
acrylamid
gel
prerun
min
electrophoresi
buffer
compos
upper
chamber
buffer
mm
tri
ph
mm
glycin
sodium
deoxychol
lower
chamber
buffer
mm
tri
ph
mm
glcine
gel
soak
sd
run
buffer
mm
tri
ph
mm
glycin
sd
min
transfer
nitrocellulos
membran
amersham
bioscienc
membran
block
pb
contain
milk
wtvol
volvol
h
blot
antibodi
ibl
japan
antibodi
signal
detect
chemiluminesc
use
secondari
antibodi
conjug
horseradish
peroxidis
ecl
detect
kit
amersham
bioscienc
inc
nj
usa
releas
human
ifna
multipl
subunit
ifnb
cultur
supernat
murin
ifna
ifnb
serum
lung
homogen
wv
mice
respons
measur
elisa
accord
manufactur
instruct
pbl
biomed
laboratori
piscataway
nj
pbmc
isol
freshli
collect
blood
use
lymphocyt
separ
medium
cellgro
per
manufactur
instruct
isol
total
pbmc
frozen
heatinactiv
fb
dmso
experiment
day
pbmc
thaw
wash
place
hr
rpmi
fb
supplement
benzonaz
tm
nucleas
novagen
prevent
cell
clump
optim
concentr
effici
activ
pbmc
minim
cytotox
ngml
data
shown
pbmc
isol
blood
patient
studi
approv
irb
vgti
florida
institut
biosafeti
committe
written
inform
consent
approv
vaccin
gene
therapi
institut
florida
inc
ethic
review
board
fwa
provid
sign
studi
particip
research
conform
ethic
guidelin
establish
ethic
committe
ohsu
vgti
martin
health
system
vsvgfp
harbor
methionin
delet
matrix
proteincod
sequenc
kindli
provid
j
bell
ottawa
health
research
institut
ca
viru
stock
grown
vero
cell
concentr
cellfre
supernat
centrifug
titrat
standard
plaqu
assay
describ
previous
recombin
vacciniagfp
viru
revert
strain
delet
mutant
kindli
provid
jingxin
cao
nation
microbiolog
laboratori
public
health
agenc
canada
winnipeg
dengu
viru
serotyp
strain
new
guinea
c
grown
insect
cell
day
briefli
cell
infect
moi
day
infect
cell
supernat
collect
clarifi
store
titer
denv
stock
determin
serial
dilut
vero
cell
intracellular
immunofluoresc
stain
denv
e
protein
h
postinfect
denot
infecti
unit
per
ml
titer
dengu
virion
determin
standard
plaqu
assay
vero
cell
plaqu
fix
stain
count
day
later
infect
experi
pbmc
cell
infect
small
volum
medium
without
fb
hour
incub
complet
medium
h
prior
analysi
hivgfp
viru
base
viru
design
coexpress
nef
egfp
singl
bicistron
rna
hivgfp
particl
produc
transient
transfect
plasmid
cell
describ
previous
briefli
cell
transfect
mg
plasmid
polyethylenimin
precipit
media
replac
h
posttransfect
viral
supernat
harvest
hr
later
clear
lowspe
centrifug
filter
mm
low
bind
protein
filter
hightit
viral
stock
prepar
concentr
viral
supernat
filtrat
column
amicon
aliquot
store
viral
titer
determin
level
elisa
briefli
serial
dilut
concentr
viral
supernat
use
infect
pbmc
two
donor
preactiv
day
mgml
pha
half
media
replac
day
day
infect
supernat
harvest
process
elisa
reedmuench
method
use
calcul
hiv
infect
monocyt
neg
select
use
easysep
human
monocyt
enrich
kit
stem
cell
per
manufactur
instruct
isol
cell
transfect
ngml
use
lyovec
invitrogen
accord
manufactur
protocol
supernat
harvest
h
stimul
briefli
centrifug
remov
cell
debri
cell
isol
use
easysep
tm
human
cell
enrich
kit
stem
cell
accord
manufactur
guidelin
purifi
monocyt
cell
allow
recov
h
rpmi
contain
fb
co
experi
hiv
infect
ab
mgml
immobil
hour
plate
cell
ad
along
ab
mgml
allow
activ
cell
day
activ
cell
incub
hour
supernat
monocyt
infect
hivgfp
moi
supernat
monocyt
left
anoth
h
ad
complet
medium
hcv
rna
synthes
use
ambion
megascript
high
yield
transcript
kit
use
linear
dna
gener
gift
takaji
wakita
nation
institut
infecti
diseas
shinjukuku
templat
cell
electropor
mg
hcv
rna
day
posttransfect
viru
contain
supernat
collect
filter
mm
store
hcvcc
cell
pretreat
ngml
h
supernat
contain
solubl
factor
induc
follow
treatment
remov
kept
asid
infect
cell
wash
pb
infect
ml
undilut
hcvcc
h
supernat
ad
back
h
postinfect
wce
prepar
express
hcv
protein
detect
western
blot
abcam
toronto
ca
influenza
strain
apuerto
kindli
provid
veronika
von
messl
dukenu
singapor
viral
stock
amplifi
madindarbi
canin
kidney
mdck
cell
viru
titer
determin
standard
plaqu
assay
cell
infect
ml
medium
without
fb
hour
inoculum
aspir
cell
incub
complet
medium
hour
prior
analysi
viral
infect
supernat
contain
solubl
factor
induc
follow
treatment
remov
kept
asid
infect
cell
wash
pb
infect
small
volum
medium
without
fb
h
supernat
ad
back
indic
period
time
percentag
cell
infect
vsv
vaccinia
hiv
determin
base
gfp
express
percentag
cell
infect
dengu
determin
standard
intracellular
stain
cell
stain
mous
mab
specif
denveprotein
clone
follow
stain
secondari
antimous
antibodi
coupl
pe
jackson
immuno
research
pbmc
infect
denv
first
stain
antihuman
alexa
fluor
ab
bd
bioscienc
cell
analyz
lsrii
flow
cytomet
becton
dickinson
compens
calcul
cell
popul
analysi
done
use
fac
diva
vivo
administr
influenza
infect
model
mice
weeksold
obtain
charl
river
laboratori
wt
mix
background
obtain
z
chen
howard
hugh
medic
institut
us
mice
obtain
tacon
mice
bred
background
intracellular
deliveri
ug
complex
vivojetpei
polyplu
franc
np
ratio
per
manufactur
instruct
administ
intraven
via
tail
vein
inject
unless
otherwis
indic
administ
day
prior
infect
day
day
infect
day
mice
isofluran
anesthesia
infect
intranas
pfu
influenza
day
viral
titer
lung
homogen
wtvol
dmem
titer
determin
standard
plaqu
assay
previous
describ
briefli
confluent
madindarbi
canin
kidney
cell
mdck
incub
ml
serial
dilut
minut
sampl
aspir
cell
overlaid
ml
agaros
dmem
plaqu
fix
count
h
later
anim
experiment
perform
accord
guidelin
canadian
council
anim
care
approv
mcgill
univers
anim
care
committe
anim
experiment
approv
inr
institut
anim
care
use
committe
five
lobe
lung
collect
fix
neutralbuff
formalin
h
organ
paraffinembed
mm
section
cut
stain
hematoxylin
eosin
stain
h
e
slide
analys
boardcertifi
independ
veterinari
pathologist
kinet
comparison
perform
two
separ
experi
cell
stimul
either
ngml
iuml
iuml
design
time
intron
purchas
schere
plough
kenilworth
nj
cell
collect
lyse
rna
extract
qiagen
valencia
ca
usa
revers
transcript
reaction
perform
obtain
cdna
hybrid
illumina
human
version
express
beadchip
accord
manufactur
instruct
quantifi
use
illumina
iscan
system
data
collect
illumina
genomestudio
softwar
first
array
display
unusu
low
median
intens
low
variabl
low
correl
rel
bulk
array
discard
rest
analysi
quantil
normal
follow
transform
use
bioconductor
packag
limma
appli
process
microarray
account
variabl
batch
data
adjust
use
combat
procedur
http
miss
valu
imput
r
packag
http
cranrprojectorgweb
packagesimputeindexhtml
order
identifi
differenti
express
gene
treat
control
untreat
sampl
limma
packag
bioconductor
use
data
mine
function
analys
gene
satisfi
pvalu
fold
chang
select
probe
map
annot
refseq
gene
control
probe
remov
expect
proport
fals
posit
fdr
estim
unadjust
pvalu
use
benjamini
hochberg
method
network
analysi
done
ingenu
pathway
analysi
ipa
ingenu
system
redwood
citi
ca
differenti
express
gene
select
base
criteria
map
ingenu
pathway
knowledg
base
differ
color
red
upregul
green
downregul
signific
associ
dataset
canon
pathway
measur
two
way
ratio
number
gene
dataset
map
pathway
divid
total
number
gene
map
canon
pathway
display
overrepresent
analysi
fisher
exact
test
use
calcul
pvalu
determin
probabl
associ
gene
dataset
canon
pathway
explain
chanc
alon
pathway
rank
pvalu
microarray
data
deposit
ncbi
gene
express
omnibu
total
rna
isol
cell
use
rneasi
kit
qiagen
valencia
ca
usa
spleen
lung
homogen
rlt
buffer
rna
isol
per
manufactur
instruct
ug
rna
revers
transcrib
use
highcapac
cdna
revers
transcript
kit
appli
biosystem
accord
manufactur
instruct
parallel
reaction
without
revers
transcriptas
includ
neg
control
rel
amount
intracellular
rna
interest
quantifi
realtim
pcr
fast
realtim
pcr
system
express
fold
chang
use
sybr
green
roch
accord
manufactur
protocol
data
present
rel
quantif
effici
correct
base
rel
express
target
gene
versu
gapdh
refer
gene
primer
set
use
studi
present
tabl
figur
quantit
realtim
rtpcr
valid
gene
induc
treatment
quantit
realtim
rtpcr
perform
valid
kinet
observ
microarray
select
gene
cell
transfect
ngml
use
lipofectamin
rnaimax
design
period
time
rna
extract
timecours
sampl
subject
realtim
rtpcr
analysi
result
repres
experi
error
bar
repres
sem
three
independ
sampl
tif
